orticosteroids in patients with COPD, the authors said, are particularly troublesome given the limited evidence for their efficacy.
In an accompanying editorial, Mark Woodhead, D.M, of Manchester (U.K.) Royal Infirmary, wrote that this report confirms secondary findings from a prospective, placebo-controlled study of an inhaled corticosteroid with long-acting antagonist that was recently published.
Given that this earlier study was not designed to analyze pneumonia frequency, its small size and high drop-out rate, he suggested, might lead a reader to reasonably conclude that its pneumonia findings were spurious.
Now, with the addition of the Canadian population-based study, Dr. Woodhead wrote, the unexpected conclusion--that drugs prescribed to prevent COPD exacerbations put patients at greater risk for severe pneumoniadeserves further consideration and study through large prospective studies with objective pneumonia definitions.
The finding of an association, he said, between pneumonia frequency and inhaled corticosteroid use in studies of different design, in different populations, and with evidence of a dose-response relations means that the findings may be real and that these observations cannot simply be dismissed.
'"/>Page: 1 2 Related medicine news :1.
One in Three Heart Attack Patients Have No Chest Pains
2.
Amphetamines Help Recovery of Stroke Patients
3.
Painkillers Do Not Shorten Dying Patients Lives
4.
Patients With Filariasis More Prone To HIV Infection5.
Glivec - New Hope For CMC Patients6.
Patients often assume wrongly that they are allergic to penicillin7.
New FDA Approved Drug NATRECOR For Heart Failure Patients8.
Hemochromatosis Patients Blood is Safe 9.
Patients Pressure Would Result In Overprescription 10.
Risk Of Decongestants In Hypertensive Patients 11.
Interference helps Heart Patients